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Abstract
Colorectal cancer (CRC) is one of the most aggressive cancers worldwide and is 
known to develop through a stepwise process involving the accumulation of several 
genetic and epigenetic alterations. Furthermore, numerous studies have highlighted 
the significant role that certain epigenetic enzymes play in CRC pathogenesis, 
particularly those that govern chromatin components in the promoter regions of 
tumor suppressors and oncogenes. Here, we delineate the relationship between 
CRC-associated epigenetic marks, their modifying enzymes, and the classification 
of CRC into distinct molecular pathways or subtypes. Moreover, we discuss some 
of the most prominent methyltransferases, demethylases, acetyltransferases, and 
deacetylases, which have been targeted for preclinical and clinical CRC treatment. 
Notably, inhibitors against these epigenetic enzymes are a promising new class of 
anticancer drugs, with several obtaining Food and Drug Administration (FDA) 
approval for the treatment of blood and solid tumors. By highlighting the epigen-
etic molecular pathways leading to CRC development as well as providing an update 
on current CRC epigenetic therapies, this chapter sheds fresh insight into new and 
emerging avenues for future therapeutics.
Keywords: checkpoint, CIMP, CIN, CRC, demethylase, DNA methylation, DNMT, 
epigenetics, HAT, HDAC, methyltransferase, MSI
1. Introduction
Colorectal cancer (CRC) is the third leading cause of cancer-related deaths glob-
ally and is expected to be responsible for an estimated 1.1 million deaths by 2030 
[1]. With this growing global burden, prevention and treatment of CRC remains 
a significant public health challenge. CRC is thought to originate from sequential 
accumulation of genetic and epigenetic aberrations [2]. Of the identified genetic 
mutations, approximately 15 have been characterized as “driver mutations” and are 
thought to be functionally important during CRC initiation and progression [3, 4].  
These include genes affecting critical cellular pathways such as those governing 
proliferation, apoptosis, migration, adhesion, and DNA damage and repair [3]. 
Importantly, it is now well established that epigenetic alterations can also serve 
as major driver events in the pathogenesis of CRC [5–7]. However, unlike genetic 
mutations, epigenetic modifications consist of heritable changes in gene expression 
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without DNA sequence changes and are intrinsically reversible by nature. These 
epigenetic events include alterations in DNA methylation, histone modifications, 
and non-coding RNAs. Moreover, the reversibility of these modifications makes 
them attractive molecular targets for anticancer therapeutic interventions [3, 8].
CRC is a highly heterogeneous disease and can be classified into molecu-
larly and pathologically distinct pathways and subtypes [9]. Moreover, these 
classifications have significantly influenced patient stratification, prognosis, 
and therapeutic response [9, 10]. In this chapter, we focus on three epigenetic-
related primary molecular pathways, namely the microsatellite instability (MSI) 
phenotype, the chromosomal instability (CIN) phenotype, and the CpG island 
methylator phenotype (CIMP). Importantly, each pathway reflects the underly-
ing mechanisms of carcinogenesis as marked by certain aberrations such as a 
defective DNA mismatch repair (MMR) system, which is associated with MSI 
CRCs [11], or by widespread promoter DNA methylation within CpG islands as is 
the case with CIMP tumors [11, 12]. On the other hand, the CIN pathway, which 
manifests in majority of CRC cases (~85%), arises through widespread chromo-
somal imbalances [9, 13, 14]. We also make mention of the relationship between 
these defined pathways and the four consensus molecular subtyping classifica-
tions, with emphasis on the frequent overlap observed between two or more of 
the aforementioned pathways.
In the past few decades, several studies have analyzed epigenetic marks, the 
enzymes mediating these marks, and the extent of their active contribution to 
CRC tumor development and progression [2, 3]. For instance, several methylation-
related enzymes have been found to be clinically relevant to CRC [15]. Among 
these, some of the most prominent histone methyltransferases (HMTs) that have 
been targeted for preclinical and clinical treatment of CRC are discussed in Section 
4 of this chapter [15, 16]. On the other hand, a comparatively less number of histone 
demethylases (HDMs) have been validated as pertinent to CRC pathogenesis. As 
important regulators of colon cell transformation, histone deacetylases (HDAC) 
have also emerged as prominent markers of early carcinogenic events due to their 
unique role in maintaining higher-order chromatin structure [17].
In this chapter, we also highlight a few chemical inhibitors relevant to epigen-
etic therapy. However, we also noted that among the CRC-associated epigenetic 
enzymes, only a few of them have potent inhibitors available [15]. This suggests that 
the knowledge concerning targeting these enzymes for CRC is still insufficient and 
needs further evaluation. For example, only a few DNA methyltransferase (DNMT) 
and HMT inhibitors have been used in CRC cells [2], and a handful of Food and 
Drug Administration (FDA)-approved HDAC inhibitors are currently being 
explored for the treatment of solid tumors including CRC [18].
Unfortunately, the use of such epigenetic-based inhibitors has not been with-
out limitations. Major drawbacks, such as adverse side effects and lack of clinical 
efficacy, have limited their use as single agents. Therefore, many inhibitors show 
more promise in combination therapy with chemotherapies suggesting that the 
full therapeutic potential of epigenetic therapy will perhaps be best realized in 
combination with other anti-cancer agents [19, 20]. This is also complemented 
by the recent understanding that there is a strong interplay between immune and 
cancer cells within the tumor microenvironment [21]. Recent studies in CRC cells 
have shown promising combinations of epigenetic and immunomodulatory drugs. 
By reversing expression changes of genes involved in immune suppression and thus 
enhancing expression of tumor-associated antigens, cancer cells potentially become 
more sensitive to immune checkpoint inhibitors [22]. These and other discoveries 
have established a highly promising basis for studies using combined epigenetic and 
immunotherapeutic agents for treating CRC.
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2. Epigenetic modifications in CRC
2.1 Histone modifications
Over the past decade, significant advances in our understanding of the CRC 
“epigenome” have revealed that most CRC cases harbor alterations in their his-
tone modification states, particularly regarding aberrant histone methylation 
and acetylation [6, 15, 23]. Importantly, these abnormal histone marks are highly 
recurrent and have recently been used as biomarkers to predict the clinical outcome 
in CRC patients [2]. These include changes in the global patterns of specific histone 
modifications. For example, Tamagawa et al. showed that global changes in histone 
H3K4me2, H3K9ac, and H3K9me2 in metachronous liver metastasis correlated to 
overall survival of CRC patients [24]. Specifically, low H3K4me2 levels were shown 
to correlate with overall poor prognosis [24]. Likewise, other studies have identified 
reduced levels of H3K9me3 and H4K20me3 as diagnostic biomarkers for CRC in cir-
culating nucleosomes which correlated with poor patient outcome [25]. Conversely, 
high H4K20me3 and H3K9me3, as well as low nuclear expression of H3K4me3, were 
associated with a better prognosis for early-stage CRC patients [26].
Furthermore, since reduction or enrichment of these marks frequently occurs at 
the promoters of key CRC-related oncogenes and tumor suppressors, this results in 
detrimental changes in gene expression that form the basis of tumorigenesis [15, 27].  
For instance, H3K4me3, when found to be elevated in CRC primary tumors and 
cell lines, resulted in activated Wingless-type (WNT) signaling and target gene 
expression via interaction between SET domain-containing protein 1A (SETD1A) 
and β-catenin [28]. Meanwhile, another study revealed that low H3K4me1/2/3 levels 
were associated with hypoxia-induced silencing of MLH1 in SW480 cells, which 
is a key event in the DNA mismatch defects linked to the development of sporadic 
CRC [29]. Yokoyama’s group also demonstrated a role for the well-recognized 
repressive mark H3K9me3, revealing that its increased levels in metastatic CRC 
patient-derived cells correlated with enhanced cell motility [30]. Interestingly, this 
coincided with repression of Ataxia-telangiectasia mutated (ATM) and p53-associ-
ated KZNF protein (APAK), leading to a defect in p53-dependent apoptosis [30]. 
Moreover, enrichment of another repressive mark, H3K27me3, was associated with 
poor CRC patient prognosis while elevated H3K79me2 was shown to enhance inter-
leukin (IL)-22-induced stemness in CRC cells [31, 32]. Intriguingly, more recent 
studies have also shown that mutations in specific methylation sites could promote 
CRC development. For instance, the Shah and Lu groups identified histone 3 lysine 
36-to-methionine (H3K36M) substitution mutations in CRC patient samples, which 
promoted more undifferentiated sarcomas in vivo [33, 34]. This suggests that H3K36 
methylation potentially constitutes a major tumor suppressive epigenetic mark.
In addition to abnormal methylation, disruption of histone acetylation pat-
terns also contributes to CRC pathogenesis, particularly relating to transcriptional 
inactivation of tumor suppressor genes and, sometimes, activation of oncogenes. 
For example, Richon et al. showed that hypoacetylation at the promoter of the 
tumor suppressor p21WAF1 led to its repression, an effect that was reversed by 
inhibition of HDAC activity [35]. Conversely, mass spectrometry-based analyses 
used to quantify global alterations of histone modifications in CRC samples identi-
fied H3K27ac as a modification frequently upregulated in CRC [36]. In fact, one 
study highlighted the effects of aspirin in reducing the enrichment of H3K27ac in 
the promoters of inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha 
(TNF-α), and IL-6 [37]. This in turn corresponded to the dramatic reduction of the 
mRNA and protein levels of these genes, which suppressed inflammatory colitis 
symptoms and CRC tumor burden [37]. Taken together, these studies emphasize 
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the differential abundance of key repressive and activating histone methylation and 
acetylation marks in CRC and suggests their role in regulating genes associated with 
CRC development and progression.
2.2 DNA methylation
DNA methylation constitutes the first recognized epigenetic alteration in CRC 
[38]. Usually, global DNA hypomethylation is frequently seen, which occurs gradu-
ally and early in the process of CRC carcinogenesis [38]. More precisely, global 
DNA hypomethylation mainly takes place on cytosine guanine (CpG) dinucleotides 
within pericentromeric regions. Initially, this hypomethylation in CRC was hypoth-
esized to be associated mainly with widespread oncogene activation but has now 
been linked predominantly to increased genomic instability [3]. This increased 
accumulation of chromosome breakage and overall chromosomal instability con-
tributes to a prevalent subtype of CRCs known as the CIN phenotype as we briefly 
described in Section 1 [39].
Notably, hypomethylation typically occurs in concert with systematic and 
discrete DNA hypermethylation events at the promoters of genes involved in DNA 
repair, apoptosis, proliferation, angiogenesis, adhesion, and invasion [38, 40]. DNA 
hypermethylation is the most extensively characterized epigenetic alteration in 
CRC, occurring at CpG dinucleotide-dense regions, called CpG islands, which are 
present in about 60% of genes [6, 41]. Apart from CpG islands, DNA hypermeth-
ylation has also been extensively observed within the first exonic/intronic regions 
of some genes and generally results in transcriptional silencing [42]. Some of the 
most frequently hypermethylated genes in CRC include Adenomatous polyposis coli 
(APC), Cyclin-dependent kinase inhibitor 2A (p16INK4a/CDKN2A), Tissue inhibitor of 
metalloproteinases 3 (TIMP3), O-6-Methylguanine-DNA methyltransferase (MGMT), 
Secreted frizzled related protein 1 (SFRP1), Transmembrane protein with epidermal 
growth factor (EGF) like and two follistatin like domains 2 (TMEFF2), Heparan 
sulfate-glucosamine 3-sulfotransferase 2 (HS3ST2/3OST2), Ras association domain 
family member 1 (RASSF1A), and GATA binding protein 4 (GATA4) [43].
Another subtype of CRCs with extensive patterns of promoter methylation, 
known as the CIMP phenotype as described in Section 1, is also characterized by 
aberrant DNA methylation at genes with roles in CRC initiation or progression 
[44]. For instance, using a qPCR-based technique, one group identified genes 
with the highest percentage of methylation in CRC patients including Runt related 
transcription factor 3 (RUNX3), Protocadherin 10 (PCDH10), Secreted frizzled related 
protein 5 (SFRP5), Insulin-like growth factor 2 (IGF2), and Hepatocyte nuclear 
factor 1 homeobox A (HNF1) homeobox B (Hnf1b) [45]. Moreover, these genes were 
observed to have the most promising biomarker potential because of the frequent 
gene repression patterns [45]. Other commonly hypermethylated genes, such as 
Sex-determining region Y (SRY)-related HMG-box (SOX17) and Apoptosis-associated 
speck-like protein containing a CARD (ASC)/target of methylation-induced silencing 
(TMS1), were differentially methylated based on the staging of the disease [46–48], 
whereas MLH1, p16, Death-associated protein kinase 1 (DAP-kinase), Ras association 
domain family member 2 (RASSF2A), and WNT inhibitory factor 1 (Wif-1) were 
regarded as plasma or serum detection markers for CRC [49].
In summary, these data strongly support the promising utility of DNA methyla-
tion as a critical diagnostic marker for CRC. Unfortunately, this has not necessarily 
translated into their prognostic or predictive use in clinical practice [50]. This can 
be attributed to significant variability in sensitivity, specificity, and reproducibility 
between diverse patient cohorts and gene expression platforms, which ultimately 
impacts the prognostic value of many tests. Currently, two FDA-approved 
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commercial tests, Epi proColon® and Cologuard, have been used for screening 
alterations in methylation of common genes, such as SEPT9, NDRG4, and BMP3, 
for early detection of CRC [51]. However, they also generally lack prognostic value 
and require improvements in terms of sensitivity and specificity. Several other 
methylation biomarker assays have also been suggested, but validation in indepen-
dent and large population screening studies is still needed [52].
2.3 Noncoding RNAs
Another epigenetic regulatory mechanism frequently deregulated in CRC 
involves the role of noncoding RNA (ncRNAs). Specifically, aberrations of microR-
NAs (miRNAs) expression, a major class of ncRNAs, are often observed in CRC and 
are considered to play a major role in tumorigenesis and CRC progression [23, 53].  
These observations are consistent with the fact that miRNAs tend to exert onco-
genic or tumor-suppressive effects. For example, miRNAs, such as miR-141, miR-
200c, miR-145, miR-373, miR-520c, miR-135a, and miR-135b, have all been shown 
to affect CRC by regulating epithelial differentiation, WNT signaling, and CRC cell 
migratory and invasive potential [54]. Other miRNAs implicated in CRC include 
miRNA-124a and miRNA-34b/34c, which were shown to regulate the cell cycle and 
TP53 pathway, respectively [55]. Several miRNAs are also associated with epithelial-
to-mesenchymal transition (EMT) in CRC. miR-15/16, miR-140, and miR-200 
family members were shown to be associated with suppression of EMT and tumor 
cell metastatic potential while miR-21 enhanced this process [56].
Other studies have highlighted that alterations in the expression pattern of miRNAs 
in CRC were considered diagnostic, prognostic, or chemosensitivity markers [57]. 
For instance, high levels of miR-320 and miR-498 were correlated with progression-
free survival in stage II CRC [58], while miR-21 abundance was associated with poor 
patient response to 5-fluorouracil adjuvant chemotherapy [59]. On the other hand, 
induced suppression of miR-21 promoted the sensitization of CRC cells to chemother-
apeutic regimens [60, 61]. Another study by Toiyama et al. demonstrated a correlation 
between elevated serum miR-200c levels and stage IV CRC compared to earlier stages. 
Furthermore, high serum miR-200c showed a significantly positive correlation with 
lymph node metastasis, distant metastasis, and prognosis [62]. A comprehensive look 
of miRNAs as CRC biomarkers is reviewed by several other sources [60].
There is also ample evidence of miRNAs being downregulated in CRC and thus 
playing tumor-suppressive roles [63]. Arndt et al. showed that reduced levels of 
miR-133a as well as enrichment of miR-224 were associated with CRC initiation [64]. 
Moreover, this study and others also revealed that CRC patients at the adenomatous 
and carcinoma stages consistently exhibited reduced steady-state levels of miR-143 and 
miR-145 [63, 64]. Another classic example includes the miR-34 family. Transfection of 
miR-34a into CRC cells led to induction of apoptosis and inhibition of cell proliferation 
in part by amplifying the p53-mediated apoptotic response [65, 66]. Intriguingly, p53 
has been shown to regulate miR-34a, suggesting a positive feedback loop between the 
two in which miR-34a could partly mediate the tumor-suppressive roles of p53 [55].
Interestingly, miRNA deregulation can also induce aberrant activity of many 
of the components of the epigenetic machinery [67]. Take DNMT3A for example, 
which has been identified as a miR-143 target and is associated with CRC via down-
regulation of miR-143 and subsequent increase in DNMT3A expression levels [68]. 
Other examples include miR-140 and miR-449, which have been shown to target 
and downregulate HDAC1 and 4, respectively, thus exerting their tumor-suppres-
sive effects [69, 70]. Taken together, these findings underscore the importance of 
miRNAs in exerting both oncogenic and antitumor roles in CRC, which may serve 
as the basis for the development of novel prognostic and therapeutic markers.
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3.  Classification of CRC pathways and subtypes using epigenetic 
features
The development of CRC occurs via aberrations in multiple genetic and 
epigenetic pathways. These pathways can be defined by three principal molecular 
phenotypes (Figure 1). As aforementioned in Section 1, these include the MSI 
phenotype, which is characterized by mutations in DNA MMR genes; the CIN 
phenotype characterized by mutations in APC/Wnt/β-catenin pathway; and a 
third CIMP, defined by global CpG island hypermethylation, which results in 
widespread silencing of tumor suppressor genes [9, 71]. Notably, each pathway 
is characterized by distinct epigenetically related pathological features that drive 
the process of tumor initiation and development. In this section, we will describe 
various epigenetic aspects of these CRC phenotypes as well as how the molecular 
aspects of each pathway have been employed as useful diagnostic and prognostic 
tools to guide the clinical management of CRC patients. Finally, we also briefly 
acknowledge how these pathways may overlap within broader systems of subtype 
classification and highlight some of the current challenges in precisely defining 
CRC subtypes.
Figure 1. 
Schematic depicting epigenetic alterations in CRC and their association with CRC molecular subtypes. The 
CRC “epigenome” harbors alterations in their histone modification states, particularly regarding aberrant 
histone methylation (blue dot) and acetylation (yellow dot). These global histone aberrations serve as 
biomarkers to predict the clinical outcome in CRC patients. DNA methylation is another major epigenetic 
alteration seen in CRC. Usually, global DNA hypomethylation occurs gradually and early in the process of CRC 
carcinogenesis. This occurs in concert with systematic and discrete CpG island hypermethylation events at the 
promoters of genes involved in DNA repair, apoptosis, proliferation, angiogenesis, adhesion, and invasion. This 
generally results in transcriptional silencing. Aberrations of micro-RNAs (miRNAs) expression, a major class 
of ncRNAs, are also often observed in CRC and are considered to play a major role in tumorigenesis and CRC 
progression. This figure also illustrates three main epigenetic-related molecular subtypes of CRC, namely the 
microsatellite instability (MSI) phenotype, the chromosomal instability (CIN) phenotype, and the CpG island 
methylator phenotype (CIMP). MSI CRCs arise from a defective DNA mismatch repair (MMR) system, which 
is associated with frameshift mutations and base pair substitutions in genes. CIMP CRCs are characterized 
by widespread promoter CpG island hypermethylation, whereas the CIN CRCs arise through widespread 
imbalances in chromosome number (aneuploidy), global hypomethylation, and loss of heterozygosity (LOH).
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3.1 Microsatellite instability phenotype (MSI)
Approximately 15–20% of all CRC cases harbor MSI [72]. Microsatellites are 
defined as repetitive one to six base pair DNA sequences distributed along coding 
and noncoding regions of the genome. Importantly, the repetitive nature of these 
regions makes them particularly susceptible to mismatch errors [72]. Tumors with 
the MSI phenotype are therefore driven by the inactivation of MMR genes, which 
are involved in repairing DNA recombination and replication errors as well cel-
lular responses to DNA damage [12]. The net effect of defective MMR machinery 
is accumulation of single base-pair mismatches, which results in a hypermutable 
cellular state [72].
MSI tumors are typically classified as MSI-high (MSI-H) or MSI-low (MSI-L). In 
MSI-H CRCs, usually two or more of the five microsatellite markers show instabil-
ity, whereas in MSI-L tumors, only one of the five markers shows instability [12]. 
If none of the markers show instability, however, these are classified as microsatel-
lite stable (MSS) CRC tumors, which account for approximately 80–85% of CRC 
patients [12]. Although majority of MSI-H tumors sporadically arise, a few are also 
linked to a familial hereditary syndrome known as Lynch syndrome or hereditary 
non-polyposis CRC (HNPCC) which account for about 3–5% of all CRC cases [12]. 
Sporadic MSI tumors are generally affected by epigenetic inactivation at the MLH1 
promoter via CpG island hypermethylation, whereas Lynch syndrome is caused by 
germline mutations in MLH1, PMS2, MSH6, or MSH2 [12].
Importantly, unlike MSS, MSI tumors are poorly differentiated and are more 
often located in the proximal colon. MSI tumors also harbor a mucinous or signet 
ring type histology and increased number of tumor-infiltrating lymphocytes 
[72]. Additionally, when MSI was first identified in CRC patients, it was shown 
that MSI-H patients tended to have a better patient prognosis compared with MSS 
tumors and had an overall lower tumor stage at diagnosis [12]. Moreover, random-
ized phase III clinical trials along with several prospective studies have shown 
that the MMR status of these patients is also predictive of response to adjuvant 
5-FU-based chemotherapy [12, 73]. The consensus was that patients with MSI-H 
tumors did not benefit from adjuvant 5-FU therapy compared to their non-MSI-H 
counterparts [73]. Furthermore, these data are consistent with other studies that 
revealed that human CRC cell lines with MSI-H phenotypes displayed resistance to 
DNA damaging agents, such as 5-FU, which could be overcome by the restoration of 
normal MMR function [74, 75].
3.2 Chromosomal instability (CIN) phenotype
The acquisition of genomic or chromosomal instability is a key feature in CRC 
development [39]. In fact, CIN has been found in approximately 85% of CRC cases 
and is characterized by increased chromosomal losses and gains as well as increased 
loss of heterozygosity [13, 14]. Although the exact mechanisms underlying CIN 
remain incompletely understood, it has been attributed to defects in genes related to 
the DNA damage response, telomere stability, and chromosomal segregation [39]. 
Unfortunately, standardizing the precise quantitative criteria that define a “CIN-
positive” tumor has been challenging due to difficulties in the detection approaches 
of chromosomal instability [39]. The approaches currently in use include cytom-
etry, karyotyping, and loss of heterozygosity analyses [76].
Along with the typical chromosomal abnormalities, accumulation of a char-
acteristic set of mutations in specific tumor suppressor genes and oncogenes is 
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also a prominent feature observed in CIN tumors [39]. These include mutations in 
APC, p53, Cyclooxygenase-2 (COX-2), and KRAS as well as 18q alterations [39]. 
Interestingly, many studies have sought to determine the prognostic value of KRAS, 
TP53, or 18q alterations. So far, evidence of increased risk of relapse or mortality in 
CRC patients with KRAS mutations has been presented, but other studies have failed 
to confirm this correlation [77]. Consequently, some of these putative individual 
prognostic markers are still undergoing rigorous study. However, several compelling 
studies indicate that the overall CIN phenotype is associated with a less favorable out-
come in patients than those with the MSI phenotype, and unlike MSI tumors, it is not 
significantly influenced by adjuvant therapy in patients with stage II–III CRC [78].
Several ongoing phase I and II clinical trials are underway to therapeutically 
target pathways that directly or indirectly initiate and perpetuate CIN. Some of 
these include small-molecule inhibitors of COX-2, Polo-Like Kinases (Plks), Eg5, 
and Centromere protein E (CENP-E) [39]. Swanton et al. also showed that CIN-
positive tumors are intrinsically resistant to taxanes due to the similarity between 
pathways that regulate the chromosomal segregation and those implicated in the 
taxane response [79]. These and other studies have collectively prompted the 
Chromosomal Instability and Anti-Tubulin Response Assessment (CINATRA) 
trial to assess whether patients with MSI-positive solid tumors derive benefit from 
EPO906 (new microtubule stabilizer) compared to patients with CIN-positive 
cancers [80]. Overall, phase I trials showed encouraging tumor control and 
response rates in patients with metastatic CRC (mCRC), although the trial was 
prematurely closed due to toxicity issues [80]. In summary, these data support the 
role of the CIN pathway in guiding patient stratification and the clinical manage-
ment of CRC. However, more studies to better define the mechanisms underlying 
CIN and determine how CIN influences progression will be critical to advance our 
understanding of the most common form of genetic instability in CRC. Moreover, 
the feasibility of standardizing detection of CIN-positive tumors and thus be able to 
target chromosomally unstable cells, will be critical.
3.3 CpG island methylator phenotype (CIMP)
The term “CpG island methylator phenotype,” or CIMP, was coined in 1999 by 
Toyota and Issa to denote the CRC tumor subtypes characterized by widespread 
promoter DNA hypermethylation at certain tumor suppressor genes [81]. More than 
50% of genes have promoters found within CpG islands [44]. Hence, the frequency 
of CIMP CRCs depends on which promoters are examined for methylation, with 
some promoters being more beneficial than others for identifying CIMP. Several 
studies have revealed that this methylation is common at the promoters of a diverse 
spectrum of genes, including Phosphatase and tensin homolog (PTEN), RUNX3, and 
Unc-5 netrin receptor C (UNC5C), making these key genes part of the expression 
signature profile in the evolution of CIMP CRCs [44]. Moreover, based on a panel 
of CIMP-specific markers coupled with the B-Raf proto-oncogene (BRAF) muta-
tional status, CIMP tumors may be further classified according to the fraction of 
promoters that exceed a certain threshold of DNA methylation as being CIMP high, 
low, or negative [44]. Although CIMP-high and CIMP-low CRCs are significantly 
associated with biological sex as well as BRAF and KRAS mutational status, these 
classifications need additional refinement [44]. Nonetheless, it is reminiscent of the 
classification of CRCs based on degrees of MSI [82].
Notably, several of the clinicopathological characteristics of CIMP-high tumors 
have also been correlated to MSI tumors [82, 83]. For example, like MSI, CIMP 
tumors also represent a clinically distinct group characterized by epigenetic instabil-
ity, distinct histological and pathological features, and discrete precursor lesions [84]. 
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Pathologically, CIMP tumors also originate similarly to MSI tumors in the proximal 
colon, with a mucinous and poorly differentiated histological type and are fre-
quently diagnosed in elderly and female patients [84, 85]. However, the determina-
tion of which specific methylated loci should be used to define CIMP remains a 
major challenge in the evaluation of CIMP tumors. Currently, several studies have 
proposed the classic panel containing the genes hMLH1 and p16 as well as Munc-
18-interacting (MINT) proteins MINT1, MINT2, and MINT31. This panel has been 
further developed to contain the genes Calcium voltage-gated channel subunit alpha1 
G (CACNA1G), Cellular retinoic acid binding protein 1 (CRABP1), IGF2, Neurogenin 
1 (NEUROG1), RUNX3, Suppressor of cytokine signaling 1 (SOCS1), Hypermethylated 
in cancer 1 (HIC1), IGF-binding protein 3 (IGFBP3), and Werner syndrome ATP-
dependent helicase (WRN) [86].
In recent years, the use of DNA hypermethylation of specific genes to predict 
CRC patient outcome and therapeutic approach has received much attention. 
Although further validation is warranted, many studies have found a correlation 
between MSS CIMP+ CRC patients and poor prognosis [87]. Furthermore, the cor-
relation between CIMP status and response to chemotherapy has been investigated. 
CIMP status predicts poor survival in metastatic MSS CRC patients treated with 
chemotherapeutic agent 5-FU [88]. Overall, patients who did not receive chemo-
therapy treatment but had tumors identified as MSS and CIMP had a worse survival 
outcome [89]. In contrast, two separate studies reported better outcomes for patients 
with CIMP tumors, a conflict that could be attributed to differences in the criteria 
used across the studies to define CIMP status. Additionally, this also suggests that the 
heterogeneous nature of CIMP tumors may warrant further classification [44].
Intriguingly, many studies have also found an association between CIMP status 
and other important epidemiological factors [90]. For instance, reports of an asso-
ciation between cigarette smoking, obesity, and CIMP showed that the number of 
cigarettes smoked as well as body mass index (BMI) had a significant relationship to 
CIMP tumor development [90, 91]. Furthermore, associations of CIMP status with 
smoking and obesity were evident only for females [90]. Taken together, the above 
evidences support a critical role of the CIMP pathway in the pathogenesis of CRC, 
which has also become a significant part of the current management of CRC. In the 
future, it will also be essential to have a consensus on a standardized panel of loci to 
define CIMP, similar to that utilized to identify MSI CRCs.
3.4 Consensus molecular subtypes
The three molecular pathways described so far also fall within several consensus 
classification systems for CRC. These systems vary in terms of the number of pro-
posed subtypes, which can range from three to six depending on the combinations 
of genetic, epigenetic, clinical, and histopathological parameters used as well as 
the extent of the overlap between the three molecular pathways. For instance, the 
Consensus Molecular Subtypes (CMS) consortium has been suggested as one of the 
most robust classification systems and describes four groups (CMS1–4) based on 
expression profiling data from multiple studies [92]. While the majority of MSI-H 
CRCs fall into the CMS1 category, CMS2–4 display higher CIN. However, CMS3 
samples have a distinctive profile compared with other CIN tumors. They tend to have 
lower CIN, higher prevalence of CIMP and close to 30% of the tumors are hypermu-
tated which confers significant overlap with MSI status tumors [93]. Additionally, the 
Cancer Genome Atlas study also demonstrated that CIMP overlaps with the MSI path-
way because of the fact that sporadic MSI-H CRCs usually harbor CIMP-high clini-
copathological features [94]. Meanwhile, CMS4 are defined as CIN-heterogeneous 
tumors with mesenchymal characteristics that occur in later disease stages [93].
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It is also noteworthy that many CRC tumors demonstrate mixed characteristics 
compatible with two or more of these subtypes, which may represent a transition 
phenotype or intratumoral heterogeneity, while others cannot be precisely classified 
into any of these pre-defined subgroups [95]. Furthermore, these classifications 
often lack incorporation of the molecular markers used for traditional TNM staging 
of CRC [96]. Taken together, these challenges as well as the existing incongruity 
between the various systems illustrate the need to further refine these consensus 
classifications by developing more progressive and integrated approaches.
4.  The role of major epigenetic enzymes in CRC and therapeutic 
strategies for targeting them
4.1 Histone methyltransferases and demethylases
As discussed so far, aberrant changes in epigenetic modifications can signifi-
cantly contribute to CRC progression. It is therefore unsurprising that many of 
the epigenetic enzymes mediating these modifications are themselves deregulated 
during the initiation and progression of CRC. Here, we describe the significance 
of changes in the expression levels of two such families of enzymes that oppose 
each other in terms of function, namely histone methyltransferases (HMTs) and 
demethylases (HDMs). Although changes in the expression or activity levels of 
several methylation-related enzymes have been linked to CRC, in most cases only 
a limited knowledge regarding the molecular mechanisms by which these enzymes 
contribute to disease development exists [15]. We summarize current knowledge 
regarding some of the preclinical validated implications of these enzymes as proof 
of principle for the employment of epigenetic agents in CRC. We also briefly discuss 
potential mechanisms of action of these enzymes as well as the advantages of 
targeting them using combinatorial over monotherapy approaches.
Histone lysine methyltransferases (HKMTs) have been widely studied across 
multiple solid tumor types including CRC [97]. For instance, studies in a preclini-
cal model of CRC found that increased expression and activity of SET and MYND 
domain containing 3 (SMYD3), a well-known HKMT, was strongly correlated 
with tumorigenesis. Moreover, RNAi-mediated depletion of SMYD3 significantly 
impaired CRC cell proliferation, indicating a crucial role of SMYD3 in maintain-
ing CRC malignancy [98]. More recent studies suggest a putative mechanism by 
which this overexpression might occur by demonstrating that hypomethylation 
of the SMYD3 promoter was observed in CRC tumor tissues compared to adjacent 
normal tissues. Further subgroup clinicopathological analyses showed that this 
hypomethylation was observed with stage III and IV tumors as defined by moderate 
to well-differentiated histology and positive lymph node metastasis [99].
Another well-studied HKMT, enhancer of zeste 2 (EZH2), is also frequently 
deregulated in CRC. Both mRNA and protein levels of EZH2 were found to be sig-
nificantly increased in CRC tissues compared to non-cancerous counterparts [16]. 
Additionally, increased EZH2 expression was directly correlated with tumor size, 
metastases, and overall worse disease-free survival of CRC patients [100]. He et al. 
also showed that siRNA-mediated depletion of EZH2 inhibited the proliferation and 
migration of SW620 CRC cells, while inducing apoptosis and G0/G1 cell cycle arrest 
[101]. Another mechanistic study also revealed that knockdown of EZH2 signifi-
cantly reduced CRC cell invasion and matrix metalloproteinases 2/9 (MMP2/9) 
secretion in vitro while promoting increased overall survival and decreased lung 
metastasis in vivo [102]. Furthermore, this EZH2-induced CRC cell invasion was 
mediated by direct binding of Signal transducer and activator of transcription 3 
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(STAT3) to the EZH2 promoter, resulting in downregulation of the vitamin D 
receptor (VDR) [102]. Interestingly, an association between a missense variant 
in EZH2 and risk of CRC was discovered by the Li group. They identified that the 
presence of the rs2302427 variant showed a significant association with increased 
CRC susceptibility [103]. Recent studies point to other mechanistic roles of HKMTs 
in CRC. For example, depletion of SETD1A, a member of the trithorax (TrxG) fam-
ily of HMTs, inhibited CRC cell growth and colony formation in part by decreasing 
expression of approximately 50% of Wnt/β-catenin target genes [28]. Finally, in 
a mouse model, IL-22-mediated activation of disruptor of telomeric silencing 1-like 
(DOT1L) promoted CRC stemness and tumorigenic potential and was considered a 
predictor of poor survival outcome in CRC patients [32].
Protein arginine methyltransferases (PRMTs), although studied to a lesser 
extent, have also been shown to play critical roles in CRC malignancy via activa-
tion of Wnt/β-catenin and NF-ĸB signaling [104]. CARM1, for example, is an 
important positive modulator of Wnt/β-catenin transcription and was found to 
promote survival and anchorage-independent growth of CRC cells with aberrantly 
activated Wnt/β-catenin signaling [105]. Meanwhile, our lab and others have shown 
that protein arginine methyltransferase 5 (PRMT5) was overexpressed in CRC cells 
and patient-derived primary tumors, which correlated with increased cell growth, 
migration, invasion, and NF-ĸB activation as well decreased overall patient sur-
vival [106–109]. The enzymes catalyzing removal of methylation marks, HDMs, 
are perhaps the least studied among the enzymes mentioned thus far and only a 
few have been implicated as playing tumor suppressive or oncogenic roles in CRC. 
LSD1, KDM4B, KDM4C, and KDM5B have all been shown to play pro-tumorigenic 
roles by promoting CRC cell growth and metastasis, whereas HDMs, such as JMJD3 
and JMJD1B, have been implicated as tumor suppressors [15]. Taken together, these 
data provide strong support for the continued development of selective and potent 
small-molecule inhibitors against these methylation-modifying enzymes as promis-
ing therapeutic agents for CRC.
4.2 Targeting HMTs and HDMs in CRC
Disruption of epigenetic regulation in CRC mediated by deregulated HMTs, 
DNMTs, and HDMs has garnered increasing interest in recent years. In this section, 
we aim to review the current status on the development of therapeutic strategies 
to modulate histone methylation for CRC treatment. The current therapeutics 
including pre-clinical and clinical agents that target epigenetic enzymes in CRC 
are listed in Table 1. Thus far, more than 20 histone-methylation enzymes have 
been found to be clinically relevant to CRC, including 17 oncoproteins and 8 tumor 
suppressors, although their exact mechanisms of action are not fully understood 
[15]. Furthermore, more than 20 small-molecule inhibitors targeting HMTs, 
DMNTs, and HDMs have been employed for preclinical or clinical studies. For 
example, treatment of DLD1 colon cell line and primary CRC cells with a potent 
HKMT inhibitor EPZ004777 (anti-DOT1L) resulted in significant reduction in 
sphere formation in vitro, thus inhibiting cell growth [32]. Other HKMT inhibitors, 
such as BCI-121 and Chaetocin, have significantly suppressed CRC cell growth and 
migration by inhibiting SMYD3 and SUV39H1, respectively [98]. Notably, inhibi-
tors against the HKMT EZH2 have yielded some of the most promising results for 
treating CRC. DZNep, an indirect EZH2 inhibitor, induced apoptosis in CRC cell 
lines and stem cells, while GSK346 impaired the migratory potential of CRC cells 
and reduced H3K27me3 levels in Colo205 and HT-29 cells (Table 1) [110].
Unlike HKMTs, the development of inhibitors against PRMTs has only recently 
gained prominence in the cancer field, and only a couple of these have made it 
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to the clinical trial phase thus far. AMI-1, which inhibits PRMT1 and PRMT5, 
demonstrated antiproliferative activity in CRC cells and xenograft mouse mod-
els [106]. However, further in vivo validation studies are needed, and it has not 
Table 1. 
Overview of pre-clinical and clinical drugs that target epigenetic enzymes in CRC.
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entered clinical trial yet. Another promising PRMT5 inhibitor that recently made 
it to Phase I clinical trials is GSK3326595, which potently inhibited tumor growth 
in vitro and in vivo [111]. Trials with GSK3326595 are currently being conducted 
in adult subjects with relapsed and/or refractory solid tumors (NCT02783300). 
Additionally, inhibitors targeting HDMs are even fewer in number and have shown 
limited efficacy in suppressing CRC cell growth. For example, KDM4A/C inhibi-
tors were ineffective in blocking HCT116 CRC cell growth when used in isolation 
[112]. However, they exhibited potent antiproliferative effects in combination with 
another HDM inhibitor, NCL-2, which targets LSD1 [113]. These data suggest a 
potential for synergy between the two classes of HDM inhibitors.
Finally, the use of DNMT inhibitors for CRC treatment has also shown some 
exciting promise. In studies using CRC cell lines, suppression of DNMT1 and 
DNMT3B resulted in significant reduction in methylation, which correlated with 
the re-expression of tumor suppressor genes. This also resulted in induction of 
apoptosis as well as reduced cell proliferation and stemness [114]. Notably, stud-
ies with the DNMT1 inhibitor, 5-aza-2′-deoxycytidine (decitabine), exhibited its 
ability to re-sensitize colorectal tumors to both irinotecan and 5-FU, thus becoming 
a major component of the treatment regimen for CRC in the clinic [19]. Another 
recent preclinical study showed that combination of the anti-EGFR inhibitor, gefi-
tinib and decitabine showed highly synergistic inhibition of CRC cell proliferation 
and migration [115]. Additional combination regimens are outlined in Table 1.
4.3 Acetyltransferases and deacetylases
Acetylation of histones by acetyltransferases (HATs) and removal of these 
acetyl marks by HDACs are essential events for the maintenance of normal chro-
matin organization and function [116]. However, as is often the case in cancer, 
these enzymes are dysregulated, leading to increased chromosomal instability 
and aberrant gene expression changes [117]. To date, only a handful of HATs 
have been reported as contributing to the pathogenesis of CRC. Here, we describe 
the role of a few of these HATs namely p300/CREB-binding protein (p300/CBP), 
GCN5, N-Acetyltransferase 10 (Nat10), and Human males absent on the first (hMOF). 
Assessment of 262 CRC samples from patients receiving 5-FU treatment dem-
onstrated that low expression of p300/CBP in CRC tissue was closely associated 
with poor clinical response to 5-FU based-chemotherapy [118]. Furthermore, low 
p300/CBP expression also correlated with poor disease-free survival and increased 
early disease progression in the same patients [118]. Mechanistic studies also 
uncovered that 5-FU induced degradation of p300/CBP which was dependent on 
chaperone-mediated autophagy involving heat-shock cognate protein 70 kDa (hsc70) 
and lysosomal-associated membrane protein 2A (LAMP2A). In short, degradation of 
p300/CBP was found to be relevant to chemoresistance to 5-FU, since blocking this 
degradation also enhanced 5-FU’s cytotoxicity in CRC cells [118].
Conversely, another HAT GCN5 has been implicated in promoting CRC cell 
growth via its upregulation rather than downregulation. One study found that 
GCN5 overexpression in human colon adenocarcinoma tissues was attributed to the 
activities of the transcription factors, c-Myc and E2F transcription factor 1 (E2F1) 
[119]. Depletion of c-Myc inhibited CRC cell proliferation mainly by downregulat-
ing GCN5 transcription, an effect that was rescued by ectopic expression of GCN5. 
However, ectopic overexpression of E2F1 had the opposite effect by suppressing 
GCN5 levels, thus inducing cell death. Furthermore, inhibition of GCN5 with 
CPTH2, a HAT inhibitor, also suppressed CRC cell growth, revealing an avenue 
of great therapeutic potential [119]. Other HATs implicated in CRC include Nat10 
and hMOF, which were downregulated in CRC tissues. Particularly, recent studies 
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showed that Nat10 downregulation and subcellular redistribution were associated 
with increased cellular motility and invasion in CRC cells [120]. Meanwhile, low 
expression of hMOF correlated with clinicopathological features of CRC such as 
lymph node metastasis and advanced tumor stage [121].
In CRC, HDACs are also frequently overexpressed and represent another attrac-
tive class of targets for anticancer therapy. HDAC1–3 and HDAC5–8 have emerged 
as some of the most relevant deacetylases in CRC. Although all are highly overex-
pressed in CRC, only few studies have explored the relevance of this overexpression 
to disease [23]. For example, knockdown of HDAC1, 2, and 3 reduced the growth 
of several CRC cells by largely unknown mechanisms [122]. Interestingly however, 
a mechanistic link between HDAC2 expression and sensitivity of CRC cells to other 
anticancer agents was recently established. Alzoubi et al. demonstrated that deple-
tion of HDAC2 specifically enhanced the combined anti-tumor effect of the pan-
HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) and the DNA-damaging 
agents, 5-FU and oxaliplatin, in SW480 and HT29 cells. On the other hand, overex-
pression of HDAC2 conferred resistance to these agents, which were independent 
of the p53 mutational status [123]. In summary, these findings strongly suggest that 
HATs and HDACs are critical biomarkers for CRC and influence the sensitivity of 
CRC cells to certain therapeutics as evidenced by their frequent combination with 
other anticancer agents (Table 1).
4.4 Targeting HATs and HDACs in CRC
Like methylation, several studies have demonstrated that inhibitors targeting 
HATs and HDACs also induce epigenetic alterations that modulate the expression 
of genes or pathways critical for CRC treatment. One study showed that direct 
inhibition of p300/KAT3B histone acetyltransferase, a coactivator of β-Catenin with 
rimonabant, induced downregulation of Wnt/β-catenin target genes in HCT116 
cells [124]. Furthermore, rimonabant also significantly reduced tumor growth in 
HCT116 xenografts [124]. The general HAT inhibitors such as garcinol and ana-
cardic acid have also been shown to inhibit CRC tumor growth in mice as well as 
sensitize cancer cells to irradiation [125].
Compared to HATs, a far greater number of studies have been dedicated to 
investigating the efficacy of HDAC inhibitors at both the preclinical and clinical 
level. Overall, the use of HDAC inhibitors in preclinical solid tumor models has 
shown some early promise albeit their progress to the clinic has been hindered by 
serious limitations including ineffective concentrations and cardiac toxicity [126]. 
In CRC specifically, these inhibitors are mainly being administered as combina-
tion therapy with conventional chemotherapy or other agents [127]. In pre-clinical 
models for instance, treatment of irinotecan-resistant CRC cells with HDAC 
inhibitors conferred sensitization of these cells to irinotecan, whereas HDAC inhibi-
tor CG2 showed an additive effect when used with irinotecan, 5-FU, or oxaliplatin 
in HCT116 xenografts [128]. Meanwhile, a small molecular inhibitor of HDAC6, 
ACY-1215, was able to enhance the anticancer activity of oxaliplatin by promoting 
apoptosis and blocking cell proliferation in CRC cells and xenograft models [129].
4.5 Benefits and pitfalls of epigenetic enzyme inhibitors
Despite their potential, a large gap still remains between the biological activity 
of epigenetic enzyme inhibitors in preclinical studies and their potential clinical 
utility. For example, the development of HAT inhibitors poses several challenges [130]. 
Because of their function in complexes consisting of many proteins which play mul-
tiple roles in HAT target specificity, this significantly limits inhibitor use in vivo [130].  
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Additionally, many undesired effects such as reactivity or lack of selectivity 
between different HAT subtypes are often associated with HAT inhibitors [130]. 
Hence, studies geared towards the development of more potent and selective inhibi-
tors by carefully studying the catalytic mechanism and enzyme kinetics of various 
HATs are needed. As far as HDAC inhibitors are concerned, they have shown 
preferential efficacy against hematological malignancies, and therefore, drugs such 
as vorinostat (SAHA) and romidepsin (FK228) have achieved FDA approval for the 
treatment of cutaneous T cell lymphoma [131, 132]. Unfortunately, the evidence 
regarding HDAC inhibitors efficacy for solid tumors has not been as convincing and 
encouraging although they are well tolerated at low but not high doses. Currently, 
adverse side effects and inadequate clinical efficacy are the major limitations to 
their use, and more efforts are underway to generate specific HDAC inhibitors for 
solid tumors such as CRC [133]. Nonetheless, a few early phase clinical trials using 
vorinostat in combination with other chemotherapeutic agents have shown some 
early promise for mCRC patients. These include combinatorial regimens of vorino-
stat with 5-FU, leucovorin, and oxaliplatin (FOLFOX) as well as randomized phase 
II trial studies investigating the efficacy of vorinostat and hydroxychloroquine or 
regorafenib in refractory mCRC patients [134, 135]. Other regimens are outlined in 
Table 1. Similarly, while DNMT inhibitors have also met with some degree of suc-
cess for treating blood cancers such as myelodysplastic syndrome (e.g., decitabine 
and 5-azacitidine), the major drawbacks of these compounds in solid tumors are 
harsh side effects and transient demethylation, which revert after drug removal 
[136, 137]. Interestingly, however, some studies have suggested that this transient 
demethylation that occurs with DNMT inhibition (e.g., 5-azadeoxycytidine) poten-
tially creates a therapeutic window that can be leveraged for epigenetic reprogram-
ming and/or combinatorial therapies with cytotoxic drugs [138].
Other general limitations regarding the use of epigenetic therapy in solid tumors 
deal with the unfavorable pharmacokinetic properties of these drugs, including 
instability, toxicity, and short half-life [137]. Some of these invariably contribute 
in some way to common toxicities associated with HDAC and DNMT inhibitors 
in CRC including thrombocytopenia, neutropenia, diarrhea, nausea, vomiting, 
and fatigue [139]. Furthermore, maintaining therapeutically relevant levels of the 
drugs necessary for clinical benefit is particularly difficult, and as of yet, no FDA-
approved epigenetic treatments exist for CRC despite promising preclinical studies. 
This signifies the overall marginal clinically compelling responses to these agents in 
CRC patients. To overcome some of these limitations, newer formulations have been 
made to render these inhibitors more bioavailable, stable, and ultimately usable at 
lower doses with less toxicity and greater therapeutic efficacy. Examples of these 
include the oral HDAC inhibitor, entinostat, used in in vitro and in vivo models of 
CRC and an orally active formulation of 5-azacitidine, cc-486 [140].
4.6 Emerging immunomodulatory and epigenetic combinatorial therapies
Compared to MSS tumors, there are an exponentially higher number of muta-
tions acquired in MSI-H CRCs. Interestingly, these mutations have the potential 
to elevate the production of neo-antigens [141]. The result is increased tumor 
immunogenicity, which is further complemented by the fact that these tumors 
also harbor a high number of tumor-infiltrating lymphocytes. Within this context, 
CRC patients with MSI-H represent a subgroup more likely to benefit from immune 
checkpoint inhibitors compared to those with MSS tumors. Immune checkpoint 
inhibitors have shown unprecedented benefit across multiple tumor types. These 
agents specifically target the proteins programmed death ligand-1 (e.g., durvalumab) 
and programmed death-1 (e.g., nivolumab, pembrolizumab) and are administered 
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as monotherapies or in combination with other anticancer agents. At the present 
time, several ongoing early and late-phase II and III clinical trials investigating 
the efficacy of immune checkpoint inhibitors in MSI-H and MSS CRC patients are 
being extensively explored including pembrolizumab (Keytruda), which recently 
obtained FDA approval (e.g., NCT01876511 and NCT02060188) [142].
Moreover, the possibility of combining epigenetic therapy and immunotherapy 
has also been recently explored, and several ongoing clinical trials in CRC investigat-
ing the combination strategies of HDACi and DNMTi with checkpoint inhibitors 
have been undertaken. Specifically, these epigenetic therapies have been shown to 
augment the effect of checkpoint inhibitors and are currently in early and late phase 
clinical trials [143]. However, since MSS subtypes represent the larger fraction of CRC 
cases, the marginal activity displayed by drugs such as pembrolizumab for treating 
MSS CRCs has been less than encouraging [144]. Hence, overcoming the clinical 
ineffectiveness of this class of drugs for this subtype remains an important need. 
Intriguingly, however, recent studies showed that treatment with 5-azacitidine and 
entinostat in CRC cell lines conferred a shift towards a CIMP+ signature, which would 
predictively convert them into a more immunogenic state [145]. This increased sen-
sitivity to immunotherapy has prompted a clinical trial evaluating this strategy, with 
the combination regimen of romidepsin (HDAC inhibitor) and cc-486 with pembro-
lizumab in MSS-CRC patients (NCT02512172) [145]. Finally, romidepsin was also 
found to potentiate 5-FU cytotoxicity in HCT-116, HT29, and SW48 cells by inducing 
apoptosis and cell cycle arrest [146]. Interestingly, MHC class II gene expression was 
also induced with this combination, once again supporting the possible cooperation 
of epigenetic therapy with immunomodulatory agents [146]. In summary, the above 
evidences support a cooperative role between epigenetic and immune therapies, 
although further efforts to optimize the epigenetic control of immune-related gene 
expression will be necessary to successfully translate these notions to the clinic.
5. Conclusion and perspectives
In this chapter, we have highlighted the pivotal contribution of epigenetic 
deregulation, specifically, DNA methylation, histone alterations, and miRNAs to the 
initiation, progression, and prognosis of CRC. We also underscored the relevance of 
these epigenetic mechanisms in terms of classifying CRC subtypes as well as their 
importance in guiding strategies for therapeutic intervention. Moreover, we empha-
sized the epigenetic enzymes that are involved in these aberrant pathways and 
presented some up-to-date findings on pre-clinical and clinical trials of epigenetic 
drugs used as single agents or in combination with conventional anticancer agents in 
CRC. Furthermore, mounting evidence demonstrates that epigenetic drugs are also 
capable of altering the immunogenicity of the CRC microenvironment and creating 
opportunities for potentiating the effects of immune checkpoint inhibitors.
Understandably, drugs targeting the cancer epigenome are also plagued 
with major challenges including lack of specificity, toxicity, and short half-life. 
Fortunately, these challenges have facilitated re-evaluation of the dosing and for-
mulation strategies for epigenetic drugs, leading to superior therapeutic drugs with 
lower toxic profiles. Another underexplored avenue includes targeting less com-
monly manipulated epigenetic mechanisms such as the use of miRNA mimics [147]. 
Furthermore, in light of the advent of personalized therapies, more intricate studies 
are also needed to elucidate the relationship between individual driver genetic 
mutations and epigenetic alterations, thus providing a pathway-driven basis for 
developing selective therapeutic strategies. This may call for a more stringent con-
trol of gene expression in CRC cells via selective targeting of epigenetic regulatory 
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enzymes. This includes the prospects of CRISPR/Cas9/Cas13-based genome and 
RNA editing, which may provide validated starting points for further development 
towards novel CRC therapeutic agents [148].
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APAK   ATM and p53-associated KZNF protein
APC   adenomatous polyposis coli
ASC/TMS1 or PYCARD  apoptosis-associated speck-like protein contain  
  ing a CARD
BET   bromodomain and extra-terminal motif
BMI   body mass index
BRAF   B-Raf proto-oncogene, serine/threonine kinase
CACNA1G   calcium voltage-gated channel subunit alpha1 G
CARM1   coactivator-associated arginine methyltransferase 1
CDKN2A/p16INK4a  cyclin-dependent kinase inhibitor 2A
CENP-E   centromere protein E
CIMP   CpG island methylator phenotype
CIN   chromosomal instability
COX-2   cyclooxygenase-2
CRABP1   cellular retinoic acid binding protein 1
CRC   colorectal cancer
DAP-kinase   death-associated protein kinase 1
DNMT   DNA methyltransferase
DNMT3A   DNA methyltransferase 3A
DOT1L   disruptor of telomeric silencing 1-like
E2F1   E2F transcription factor 1
Eg5   kinesin 5 family member
EMT   epithelial-to-mesenchymal transition
EZH2   enhancer of zeste 2
FDA   Food and Drug Administration
5-FU   5-fluorouracil
GATA4   GATA-binding protein 4
HAT   histone acetyltransferase
HDAC   histone deacetylase
HDM   histone demethylase
HIC1   hypermethylated in cancer 1
HKMT   histone lysine methyltransferase
HKMTs   histone lysine methyltransferases
hMLH1   human mutL homolog 1
hMOF   human males absent on the first
HMT   histone methyltransferase
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Hnf1b  HNF1 homeobox B
HNPCC  hereditary non-polyposis colon cancer
HS3ST2 (3OST2) heparan sulfate-glucosamine 3-sulfotransferase 2
hsc70  heat-shock cognate protein 70 kDa
IGF2  insulin-like growth factor 2
IGFBP3  insulin-like growth factor binding protein 3
IL-6  interleukin 6
iNOS  inducible nitric oxide synthase
KDM  lysine demethylase
KRAS  Kirsten rat sarcoma 2 viral oncogene
LAMP2A  lysosomal-associated membrane protein 2A
LOH  loss of heterozygosity
mCRC  metastatic colorectal cancer
MGMT  O-6-methylguanine-DNA methyltransferase
MINT  Munc-18-interacting
miRNA  microRNA
MLH1  mutL homolog 1
MSH2, 6  MutS protein homolog 2, 6
MSI  microsatellite instability
MSS  microsatellite stable
Nat10  N-acetyltransferase 10
NEUROG1  neurogenin 1
nRNA  noncoding RNA
p300/CBP  p300/CREB-binding protein
p53 or TP53  tumor protein 53
PCDH10  protocadherin 10
PD-1  programmed death-1
PDL-1  programmed death ligand-1
Plks  polo-like kinases
PMS2  PMS1 homolog 2, mismatch repair system component
PRMT  protein arginine methyltransferase
PRMT5  protein arginine methyltransferase 5
PTEN  phosphatase and tensin homolog
RASSF1A  ras association domain family member 1
RASSF2A  ras association domain family member 2
RUNX3  runt-related transcription factor 3
SAHA  suberoylanilide hydroxamic acid
SETD1A  SET domain-containing protein 1A
SFRP1  secreted frizzled related protein 1
SFRP5  secreted frizzled related protein 5
SMYD3  SET and MYND domain containing 3
SOCS1  suppressor of cytokine signaling 1
SOX17  SRY-Box 17
STAT3  signal transducer and activator of transcription 3
SUV39H1  suppressor of variegation 3–9 homolog 1
TIMP3  tissue inhibitor of metalloproteinases 3
TMEFF2  transmembrane protein with EGF-like and two  
               follistatin-like domains 2
TNF-α  tumor necrosis factor alpha
UNC5C  Unc-5 netrin receptor C
Wif-1  WNT inhibitory factor 1
WNT  wingless type
WRN  Werner syndrome ATP-dependent helicase
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